Status of treatment and outcome in Kawasaki disease in the Kinki area of Japan

Pediatr Int. 2022 Jan;64(1):e15391. doi: 10.1111/ped.15391.

Abstract

Background: The treatment guidelines for acute Kawasaki disease (KD) have been revised several times. Moreover, the criterion used to define coronary artery abnormalities (CAAs) has changed from the coronary artery's internal diameter to the Z-score. Treatment for KD and methods for evaluating CAAs vary between hospitals, so we investigated the actual status of acute KD treatment and development of CAAs under the 2012 Japanese treatment guidelines for acute KD.

Methods: The 24th Japanese Nationwide Survey on Kawasaki Disease yielded 2618 patients who developed KD in the Kinki area in 2016. We sent a secondary questionnaire to each participating hospital and used the resulting data to investigate the frequency of CAAs according to Z-score, treatment by KD treatment stage, and predictors of CAAs.

Results: The response rate was 80.0%. The data for 1426 patients without major data deficiencies were examined. The frequency of CAAs was 3.0% when based on coronary artery internal diameters and 8.8% when based on Z-scores. Intravenous immunoglobulins combined with corticosteroids were administered as an initial treatment in 12.8% of cases and as a second-line treatment in 16.8% of cases. Corticosteroids, cyclosporine A, infliximab, and plasma exchange were used at similar frequencies for third-line treatment. A pretreatment maximum coronary artery Z-score of ≥1.9 and age <1 year were associated with significantly higher incidences of CAAs.

Conclusions: Using the Z-score resulted in a threefold increase in the number of patients diagnosed with CAAs. A pretreatment maximum coronary artery Z-score of ≥1.9 and age <1 year are useful predictors of CAAs.

Keywords: Kawasaki disease; Z-score; acute treatment; coronary artery abnormality; epidemiology.

MeSH terms

  • Coronary Artery Disease* / epidemiology
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use
  • Infant
  • Japan / epidemiology
  • Mucocutaneous Lymph Node Syndrome* / diagnosis
  • Mucocutaneous Lymph Node Syndrome* / epidemiology
  • Mucocutaneous Lymph Node Syndrome* / therapy
  • Retrospective Studies
  • Treatment Outcome

Substances

  • Immunoglobulins, Intravenous